URL has been copied successfully!
Greg Verdine is having a very good year.
The scientist-turned-biotech entrepreneur has been basking in the knowledge that the science he had tried to propel forward nearly 15 years ago may have changed the landscape for pancreatic cancer patients.
His more recent ventures are taking off. One, Parabilis Medicines, went public in June in one of the industry’s largest IPOs in recent years. The other, LifeMine, has raised $263 million, it announced Thursday, enough to advance a drug that Verdine believes could make organ transplants more viable and potentially help people with autoimmune conditions.
Please follow us:
